Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.

• Autores: Jonathan C. Cho, Shyanne C. Locke, A. D. Le
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 54, Nº. 6, 2018, págs. 361-368
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Letermovir is a new antiviral agent with activity against human cytomegalovirus (CMV). Letermovir works as an inhibitor of the CMV DNA terminase complex which further inhibits viral DNA processing and packaging. Letermovir is available both orally and intravenously in 480-mg and 240-mg dosage forms, and is approved for use in the prophylaxis of CMV infection and disease in CMV-seropositive recipients of allogeneic hematopoietic stem cell transplant (HSCT) over the age of 18. The recommended dose is 480 mg p.o./i.v. once daily initiated between day 0 through day 28 post-allogeneic HSCT and continued through day 100 post-transplantation; the dose should be reduced to 240 mg daily if coadministered with cyclosporine. Letermovir is metabolized primarily by hepatic OATP1B1/3 and is not recommended for patients with severe hepatic impairment (Child-Pugh class C). Renal dosage adjustments are not warranted until a creatinine clearance (CrCl) of < 10 mL/min; however, serum creatinine should be monitored when administered to patients with a CrCl of < 50 mL/min. Cross-resistance with other useful antiviral agents in the treatment of CMV has not been observed. Additionally, letermovir is active against DNA polymerase inhibitor-resistant viral strains. Letermovir has shown promising clinical efficacy and is generally well tolerated, thus providing a favorable new option in the prophylaxis of CMV infection and disease.